Abstract
Endocannabinoids (eCBs) are internal lipid mediators recognized by the cannabinoid-1 and -2 receptors (CB1R and CB2R, respectively), which also mediate the different physiological effects of marijuana. The endocannabinoid system, consisting of eCBs, their receptors, and the enzymes involved in their biosynthesis and degradation, is present in a vast number of peripheral organs. In this review we describe the role of the eCB/CB1R system in modulating the metabolism in several peripheral organs. We assess how eCBs, via activating the CB1R, contribute to obesity and regulate food intake. In addition, we describe their roles in modulating liver and kidney functions, as well as bone remodeling and mass. Special importance is given to emphasizing the efficacy of the recently developed peripherally restricted CB1R antagonists, which were pre-clinically tested in the management of energy homeostasis, and in ameliorating both obesity- and diabetes-induced metabolic complications.
| Original language | English |
|---|---|
| Pages (from-to) | 23-29 |
| Number of pages | 7 |
| Journal | European Journal of Internal Medicine |
| Volume | 49 |
| DOIs | |
| State | Published - Mar 2018 |
Bibliographical note
Funding Information:This research was supported by an Israel Science Foundation grant ( #617/14 ), and an ERC-2015-StG grant ( #676841 ) to J.T.
Publisher Copyright:
© 2018 European Federation of Internal Medicine
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Bone remodeling
- CB receptor
- Chronic kidney disease
- Endocannabinoids
- NAFLD
- Obesity
Fingerprint
Dive into the research topics of 'The therapeutic potential of targeting the peripheral endocannabinoid/CB1 receptor system'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver